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Patients presenting with a clinical phenotype indicative of neuromyelitis optica spectrum 
disease (NMOSD) including its limited variants such as recurrent optic neuritis (ON) or 
longitudinally extensive transverse myelitis (LETM) negative for AQP-4-antibodies, may test 
positive for IgG antibodies against myelin oligodendrocyte glycoprotein (MOG), a 
transmembrane protein expressed on oligodendrocytes and the outer layers of the myelin 
sheath. MOG antibody associated autoimmunity has gained increasing attention over recent 
years due to its clinical overlap with NMOSD, despite the latter being considered an 
autoimmune astrocytopathy. Anti-MOG-antibody positive patients show a relapsing disease 
course that can lead to substantial visual loss and spinal cord involvement.1-3 Data on therapy 
in MOG-antibody associated disease as of yet is limited, but similar to NMOSD, it appears 
critical to start an efficacious treatment early in order to prevent severe functional sequelae 
including blindness. Tocilizumab (TCZ), a humanized antibody targeting the Interleukin 6 (IL6) 
receptor, has shown promise in patients with breakthrough disease and highly active forms of 
AQP-4-antibody positive NMOSD.4, 5 Prolonged treatment with TCZ has been reported both 
efficacious and safe5 and leading to a reduction of AQP-4 antibody titers 4, 5. 
Here we present a case of an anti-MOG seropositive patient, who is stable on TCZ for more 
than 4.5 years after having failed various immunotherapies including the anti-CD20 antibody 
rituximab and cyclophosphamide.  
Case report 
A 59-year old male Caucasian patient was admitted to our hospital due to gait ataxia, urinary 
retention, constipation, nystagmus and double vision. The initial MRI showed multiple, non-
longitudinally extensive T2 hyperintense lesions in the cervical, thoracic and lumbar spinal 
cord, as well as lesions in both thalami and the pons (figure 1). Short-term MRI follow-up 
indicated progressive hyperintense lesions in the cervical cord with Gadolinium (Gd) 
enhancement. CSF analysis revealed 15 mononuclear cells per µl and an elevated protein of 
906 mg/l, whereas oligoclonal bands were negative. The patient was tested negative for anti-
AQP-4-antibody twice. Extensive bacteriological and virology screenings remained 
unremarkable, and the patient improved upon high dose steroids. Three months later he 
developed ON of the right eye followed by 6 relapses over the following 19 months while the 
left eye was affected once. Every relapse was treated with high dose steroids followed by 
plasmapheresis once with only partial recovery leading to a residual visual acuity (VA) below 
20/400 (Snellen chart) on the right. Initially, treatment with the anti-VLA4 monoclonal antibody 
natalizumab had been initiated (3 administrations in total) followed by rituximab (2x 1g in 2 
weeks) due to disease breakthrough (see figure). Due to further relapses the patient was 
switched to cyclophosphamide (in total 12 administrations). Following further clinical- and MRI 
breakthrough activity (relapsing ON) and suspected seronegative NMO, monthly TCZ (8mg/ 
kg bodyweight) was initiated for 12 months and then tapered to applications every 6 weeks. 
Meanwhile the patient was tested positive for anti-MOG-antibodies (titer 1:320). Currently, a 
2-monthly TCZ regime is installed. No further relapses occurred, MRI remained stable 
throughout, new lesions were not detected.   
Discussion 
MOG antibody-associated disease can present with relapsing disease leading to severe 
functional deficits including amblyopia and severe spinal cord syndrome.1, 2 Efficacious 
immune treatment should therefore be installed early. Currently, no treatment consensus 
exists for this relatively novel entity. We observed natalizumab not only failing to control but 
worsen disease activity, which has similarly been reported for AQP-4-antibody positive cases.6 
We suggest that, similar to AQP4-antibody positive NMOSD, the administration of TCZ in MOG 
antibody associated autoimmunity should be evaluated early as well as in cases of treatment 
failure to anti-CD20 therapy (rituximab).7 Our single case report without controls provides class 
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IV evidence on the efficacy of the IL-6 antibody TCZ in MOG-antibody associated 
autoimmunity.  
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Figure 1. MRI findings, treatment history and relapse timeline.  
 
Figure legend: (A) MRI scans: left: T2-hyperintense bilateral thalamic and extensive longitudinal 
lumbar spinal cord lesion; right: follow-up scan 8 months later without T2-hyperintense lesions. (B) 
Timeline of treatment interventions: ON: optic neuritis. 
